ArticleClinical neuroradiology2015
Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
Article in Clinical neuroradiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review.The British journal of radiology · 2018Pooled it
- MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.European radiology · 2018Trial
- Exploring the role of advanced MRI in understanding glioblastoma biology: A scoping review protocol.MethodsX · 2026Article
- Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma.BMC cancer · 2026Article
- Exploring the Role of Advanced MRI in Understanding Glioblastoma Biology: A Scoping Review.Cancers · 2026Review
- Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.La Radiologia medica · 2025Review
- Imaging-Based Molecular Characterization of Adult-Type Diffuse Glioma Using Diffusion and Perfusion MRI in Pre- and Post-Treatment Stage Considering Spatial and Temporal Heterogeneity.Journal of magnetic resonance imaging : JMRI · 2025Article
- -New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Imaging Genomics of Glioma Revisited: Analytic Methods to Understand Spatial and Temporal Heterogeneity.AJNR. American journal of neuroradiology · 2024Review
- Article
- Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.Journal of neuro-oncology · 2023Article
- Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.The neuroradiology journal · 2023Article
- Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.Cancers · 2022Article
- An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas.Brain : a journal of neurology · 2022Article
- Review
- Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.Journal of personalized medicine · 2022Review
- New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme.Exploration of targeted anti-tumor therapy · 2022Review
- Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma.Neuroradiology · 2021Article
- Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma.Cancers · 2021Article
- MRI Features May Predict Molecular Features of Glioblastoma inAJNR. American journal of neuroradiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
background and purposeMolecular and genetic testing is becoming increasingly relevant in GBM. We sought to determine whether dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion imaging could predict EGFR-defined subtypes of GBM. MATERIALS AND
methodsWe retrospectively identified 106 consecutive glioblastoma (GBM) patients with known EGFR gene amplification, and a subset of 65 patients who also had known EGFRvIII gene mutation status. All patients underwent T2* DSC MRI perfusion. DSC perfusion maps and T2* signal intensity time curves were evaluated, and the following measures of tumor perfusion were recorded: (1) maximum relative cerebral blood volume (rCBV), (2) relative peak height (rPH), and (3) percent signal recovery (PSR). The imaging metrics were correlated to EGFR gene amplification and EGFRvIII mutation status using univariate analyses.
resultsEGFR amplification was present in 44 (41.5 %) subjects and absent in 62 (58.5 %). Among the 65 subjects who had undergone EGFRvIII mutation transcript analysis, 18 subjects (27.7 %) tested positive for the EGFRvIII mutation, whereas 47 (72.3 %) did not. Higher median rCBV (3.31 versus 2.62, p = 0.01) and lower PSR (0.70 versus 0.78, p = 0.03) were associated with high levels of EGFR amplification. Higher median rPH (3.68 versus 2.76, p = 0.03) was associated with EGFRvIII mutation.
conclusionDSC MRI perfusion may have a role in identifying patients with EGFR gene amplification and EGFRvIII gene mutation status, potential targets for individualized treatment protocols. Our results raise the need for further investigation for imaging biomarkers of genetically unique GBM subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.